Align Summit: Cambridge based Quiver Bioscience is developing ASOs for CNS conditions, including having programs in the red hot Nav1.7/1.8 pain space
Co-Founder & CEO Graham Dempsey describes the different between Nav1.7 and 1.8, and why he thinks having an ASO approach will succeed in 1.7 where small molecules have not. Plus, an epilepsy program, and what it is like being an earlier stage company today.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.